Medical Advocates
Nucleoside/Nucleotide RTIs
  Adverse Events

General Reports
 Cancer
 Cardiovascular Disorders
Hepatic Disorders
 Metabolic Disorders
Renal Disorders
Hyperlactatemia
 Lactic Acidosis
Mitochondrial Disorders
Myopathy
 Pancreatitis		  
NRTI Main Page Main New/Newsworthy Home Page
Last Update:  November 14, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Toxicities Associated with Dual Nucleoside Reverse-Transcriptase Inhibitor Regimens in
HIV-Infected Children.
 Van Dyke RB, Wang L, Williams PL, et al
J Infect Dis. 2008 Dec 1;198(11):1599-608
 Abstract  

Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors.
 Olivero OA.   
Environ Mol Mutagen. 2006 Jan 4;
Abstract  
Cancer
 

     Journal Papers, Abstracts, and Commentaries

  Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.
 Benhammou V, Warszawski J, Bellec S, et al 
AIDS. 2008 Oct 18;22(16):2165-2177.
 Abstract  
Cardiovascular Disorders
 
     Journal Papers, Abstracts, and Commentaries 
 
  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction
in HIV-infected patients.
 The SMART/INSIGHT and the D:A:D Study Groups.
AIDS. 2008 Aug 20.
Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
enrolled in the SMART study
 J. Lundgren, J. Neuhaus, A. Babiker, et al
(XVII International AIDS Conference)
 Abstract

BMI and long-term NRTI treatment are significantly associated with hypertension
10 years after PI-ART start
 G Bratt, S Liljeqvist, C Ek, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract

Targeted Cardiac Overexpression of the Deoxynucleoside Carrier in Murine
Myocardium Causes Mitochondrial Cardiomyopathy with Administration of
HAART: Implications for NRTI Intracellular Processing and Toxicity
 William Lewis, Y Miller, C Haase, et al
(12 CROI)
Abstract
Hepatic Disorders
     

     Journal Papers, Abstracts, and Commentaries 

  Nucleoside induced hepatopathy in HIV patients Diagnostic value of liver biopsy
assessment
 Haas S, Rockstroh JK, Spengler U, Fischer HP.
 Pathologe. 2004 Jun 4
 Abstract 
 
  Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency
virus-infected patients receiving nucleoside analogue combination regimens.
Lonergan JT, Behling C, Pfander H, et al.
Clin Infect Dis 2000 Jul;31(1):162-6
 Abstract 
Metabolic Disorders: General
 

     Journal Papers, Abstracts, and Commentaries

 
Brief Report: Insulin Resistance Is Affected by Increased Levels of Plasma Lactate but not
Mitochondrial Alterations in Skeletal Muscle in NRTI-Exposed HIV-Infected Patients.
 Maagaard A, Holberg-Petersen M, Torjesen PA, et al
HIV Clin Trials. 2007 Sep-Oct;8(5):345-53.
Abstract 
 
Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial
Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
 Shikuma CM, Yang Y, Glesby MJ, et al
J Acquir Immune Defic Syndr. 2007 Jan 22;
 Abstract 
 

Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons
Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or
Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strategy.
 Shlay JC, Bartsch G, Peng G, et al  
 J Acquir Immune Defic Syndr. 2007 Feb 22;
 Abstract  
 
     Conference Reports, Abstracts, and Posters
 
  Nucleoside reverse transcriptase inhibitor (NRTI) - induced hyperlactatemia/lactic acidosis at a
tertiary communicable disease clinic (CDC) in South Africa
 E. Hernández Pérez, H. Dawood  
(XVII International AIDS Conference)
 Abstract
Renal Disorders
 

     Conference Reports, Abstracts, and Posters

  Renal tubular acidosis related to nucleoside reverse transcriptase inhibitor (NRTI) containing
HAART regimen. An unusual case report
 A Goyenechea, P Rivas, J Alonso, et al
 (15IAC)
 Abstract
Hyperlactatemia
 

    Journal Papers, Abstracts, and Commentaries 

  FULL-TEXT ARTICLE
Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.
 Hocqueloux L, Alberti C, Feugeas JP,  
 HIV Med 2003 Jan;4(1):18-23
Paper
 
FULL-TEXT ARTICLE
 Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.
 Antoniou T, Weisdorf T, Gough K.
CMAJ 2003 Jan 21;168(2):195-8
 Paper
 
Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
 Vrouenraets SM, Treskes M, Regez RM, et al. 
Antivir Ther 2002 Dec;7(4):239-44
 Abstract
 
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy   
 John M, Moore CB, James IR, et  al.
AIDS 2001 Apr 13;15(6):717-23
Abstract 
 
Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency
virus-infected patients receiving nucleoside analogue combination regimens.
Lonergan JT, Behling C, Pfander H, et al.
Clin Infect Dis 2000 Jul;31(1):162-6
 Abstract 
Lactic Acidemia/Acidosis
 

    Journal Papers, Abstracts, and Commentaries 
  Lactic acidosis related to nucleoside therapy in HIV-infected patients.
 Falco VV, Crespo M, Ribera E 
Expert Opin Pharmacother. 2003 Aug;4(8):1321-1329.
Abstract 
 		    
  Bench-to-bedside review: Severe lactic acidosis in HIV patients treated with nucleoside
analogue reverse transcriptase inhibitors.
 Claessens YE, Chiche JD, Mira JP, Cariou A.
Crit Care. 2003 Jun;7(3):226-32.
Abstract 
 		    
  Lactic acidosis associated with nucleoside analog therapy in an HIV-positive patient.
 Goldfarb-Rumyantzev AS, Jeyakumar A, et al.
AIDS Patient Care STDS 2000 Jul;14(7):339-42
 Abstract
 		    

     Conference Reports, Abstracts, and Posters

  Incidence and Outcome of Hyperlactatemia Associated with Clinical Manifestations in
HIV-Infected Adults Receiving NRTI-Containing Regimens
 (CROI)
 Abstract
 
  Hyperlactatemia in HIV-Infected Patients: The Role of NRTI Treatment.
(8 CROI)
 Abstract
Mitochondrial Disorders
 

     Journal Papers, Abstracts, and Commentaries

 
A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
 Kohler JJ, Lewis W  .
 Environ Mol Mutagen. 2006 Jun 6;
 Abstract

Nucleoside-Related Mitochondrial Toxicity among HIV-Infected Patients Receiving
Antiretroviral Therapy: Insights from the Evaluation of Venous Lactic Acid and
Peripheral Blood Mitochondrial DNA.
 Montaner JS, Cote HC, Harris M, et al
 Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S73-9.
 Abstract
 
  Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective.
 Lewis W, Day BJ, Copeland WC.
Nat Rev Drug Discov. 2003 Oct;2(10):812-22.
 Abstract
 
  Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy:
experimental clarifications and persistent clinical questions.
 Lewis W
 Antiviral Res 2003 May;58(3):189-97
Abstract
 
  Toxic effects of nucleoside reverse transcriptase inhibitors on the liver.Value of electron
microscopy analysis for the diagnosis of mitochondrial cytopathy.
 Van Huyen JP, Landau A, Piketty C, et al.
Am J Clin Pathol 2003 Apr;119(4):546-55
 Abstract
 
  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.
 Cote HC, Brumme ZL, Craib KJ, et al.
 N Engl J Med 2002 Mar 14;346(11):811-20
Abstract
Myopathy
 
  Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential
benefit of coenzyme Q(10) therapy.
Rosenfeldt FL, Mijch A, McCrystal G, et al
Int J STD AIDS. 2005 Dec;16(12):827-829
 Abstract
Pancreatitis
 

     Journal Papers, Abstracts, and Commentaries

  Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase
inhibitor drugs.
 Keruly JC, Chaisson RE.
AIDS 2001 Mar 30;15(5):617-20
 Abstract 
 

 

NRTI Main Page Main New/Newsworthy Home Page

Nucleoside Reverse Transcriptase Inhibitors  Adverse Events